Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended September 30, 2001 (First Quarter of Fiscal Year 2002)
Business Overview: The Company operates in four segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services.
Key Financial Metrics
| Metric | Q1 2002 (Sep 30, 2001) | Q1 2001 (Sep 30, 2000) |
|---|---|---|
| Total Revenue | $11,773.4 million | $11,039.9 million |
| Operating Revenue | $9,865.4 million | $8,510.9 million |
| Gross Margin | $914.7 million (9.27% of Op. Rev) | $804.2 million (9.45% of Op. Rev) |
| Operating Earnings | $400.0 million | $324.5 million |
| Net Earnings | $176.3 million | $190.0 million |
| Diluted EPS (Net) | $0.38 | $0.42 |
| Cash and Equivalents | $872.0 million | $573.3 million |
| Working Capital | $4.9 billion | $4.1 billion (Jun 30, 2001) |
| Long-term Obligations | $2,288.6 million | $1,871.0 million (Jun 30, 2001) |
Cash Flow: Net cash used in operating activities was $480.7 million, primarily driven by a $1.4 billion increase in inventories. Net cash provided by financing activities was $467.3 million.
Material Changes vs. Prior Period
- Revenue Growth: Total operating revenue increased 16% year-over-year, driven by higher sales volume, pharmaceutical price increases, acquisitions (specifically Bergen Brunswig Medical Corporation), and new customer additions.
- Margin Compression: Gross margin percentage decreased from 9.45% to 9.27%. This was primarily due to a higher mix of lower-margin distributed products, particularly in the Pharmaceutical Distribution and Medical-Surgical segments.
- Inventory Build: Inventories increased by $1.4 billion ($6,286.1 million to $7,704.7 million) to support higher business volume and emergency-response readiness initiatives.
- Accounting Changes: The Company adopted SFAS 142, ceasing the amortization of goodwill and intangible assets with indefinite lives. Additionally, revenue recognition for pharmacy automation equipment changed from delivery to installation, resulting in a one-time cumulative effect charge of $70.1 million (net of tax) that reduced net earnings.
- Special Charges: Merger-related costs totaled $12.3 million for the quarter, consistent with the prior year, related to integrating Bindley, BBMC, ALP, Allegiance, and Scherer.
Guidance, Outlook, and Risks
- Future Costs: Management estimates approximately $130.0 million ($80.6 million net of tax) in additional merger-related and integration costs will be incurred in future periods (primarily fiscal 2002 and 2003).
- Share Repurchase: The Board authorized a $500 million share repurchase program in September 2001; no shares had been repurchased as of the period end.
- Litigation Risk: The Company faces approximately 609 lawsuits regarding natural rubber latex glove sensitization (inherited from the Allegiance acquisition). While a settlement regarding insurance reimbursement was reached in October 2001, the Company anticipates significant ongoing defense costs and believes a substantial portion of liability will be covered by insurance.
- Market Risk: No material changes in market risk exposure were reported compared to the prior fiscal year.
Investor Verification Checklist
- Inventory Levels: Verify the sustainability of the $1.4 billion inventory increase and its impact on future working capital requirements.
- Accounting Impact: Confirm the long-term effect of the revenue recognition change for automation equipment on future quarterly earnings.
- Merger Integration: Monitor the realization of the estimated $130 million in future merger-related costs and the timeline for integration synergies.
- Latex Litigation: Track the resolution of the 609 pending latex glove lawsuits and the actual recovery of defense costs from insurers.
- Margin Trends: Assess whether the shift toward lower-margin distributed products is a temporary acquisition effect or a structural change in the business mix.